期刊文献+

替加环素联合治疗泛耐药肺炎克雷伯菌菌血症病例分析 被引量:5

Case analysis of extensive drug resistant Klebsiella pneumoniae bacteremia treated with tigecycline combined therapy
原文传递
导出
摘要 目的探讨替加环素治疗泛耐药肺炎克雷伯菌所致菌血症的临床疗效。方法对1例使用替加环素治疗泛耐药肺炎克雷伯菌菌血症的病例进行分析。结果和结论替加环素是联合治疗泛耐药肺炎克雷伯菌菌血症的一种选择。 Objective To investigate the efficacy of tigecycline in the treatment of bacteremia caused by extensive drug resistant Klebsiella pneumoniae. Methods To analyse a case of extensive drug resistant Klebsiella pneumoniae bacteremia treated with tigecyeline combined therapy. Results and conclusion Tigecycline is an option in the combinative treatment of extensive drug resistant Klebsiella pneumoniae bacteremia.
作者 郑敬 苑鑫 刘永辉 牛文凯 李逢将 柏长青 ZHENG Jing YUAN Xin LIU Yong - hui NIU Wen - kai LI Feng - jiang BAI Chang - qing(Department of Respiratory and Critical Care Unit, Affiliated Hospital of Academy of Military Medical Science, Beijing 100071, China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2017年第8期742-744,共3页 The Chinese Journal of Clinical Pharmacology
关键词 替加环素 泛耐药肺炎克雷伯菌 菌血症 tigecycline extensive drug resistant Klebsiella pneumonia bacteremia
  • 相关文献

参考文献3

二级参考文献31

  • 1孙自镛,程黎明,朱旭慧,李丽,张蓓.超广谱β-内酰胺酶基因型分析[J].华中科技大学学报(医学版),2006,35(6):819-821. 被引量:2
  • 2Clinical and Laboratory Standads Institute. Performance Standards for Antimicrobial Susceptibility Testing [S J . Sixteenth Informational Supplement. 2012 .M100-S22.
  • 3Tygacil (tigecycline) iv injection label - US FDA [S]. 2013. Reference ID: 3379756. http://www. accessdata. fda. gov/ drugsatfda_docs/labeI/2013 /021821 s026s031lbl. pdf.
  • 4Clinical and Laboratory Standads Institute. Performance Standards for Antimicrobial Susceptibility Testing [S J . Sixteenth Informational Supplement. 2011 ? M100-S21.
  • 5Tsai YK. Liou CH. Fung CPo et al. Single or in combination antimicrobial resistance mechanisms of Klebsiella pneumoniae contribute to varied susceptibility to different carbapenems [J]. PLoS One. 2013:8(11): e79640.
  • 6van Duin D. Kaye KS. Neuner EA. et aI. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes[J]. Diagn Microbiol Infect Dis. 2013.75(2): 115-120.
  • 7Zarkotou O. Pournaras S. Altouvas G. et al. Comparative evaluation of tigecyciine testing methods for expandedspectrum cephalosporin and carbapenem-resistant gramnegative pathogens [J]. J Clin Microbiol , 2012. 50 (11) : 3747-3750.
  • 8Huang TD. Berhin C. Bogaerts P. et al. In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tiyecyciine[J]. J Antimicrob Chemother , 2012. 67 (11): 2696-2699.
  • 9Nordmann P,Cuzon G,Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria[J].Lancet InfecL Dis,2009.228-236.
  • 10Clinical and Laboratory Standards Institute. M100-S20.Performance standards for antimicrobial susceptibility testing;twentieth informational supplcment[S].Wayne:CLSI,2010.

共引文献104

同被引文献44

引证文献5

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部